Federal Appeals Court Restricts Mailing of Mifepristone, Impacting Abortion Access Nationwide
A federal appeals court has issued a ruling that restricts the mailing of mifepristone, a drug commonly used for medication abortions, marking a significant shift in U.S. abortion policy. The New Orleans-based 5th U.S. Circuit Court of Appeals decided that mifepristone must be distributed in person at clinics, overturning previous FDA regulations that allowed the drug to be mailed. This decision affects all states, including those where abortion remains legal, such as California. The ruling is seen as a victory for abortion opponents who argue that mailing the drug undermines state bans on abortion. The case is expected to be appealed to the U.S. Supreme Court. 
